Conduit Pharmaceuticals Stock Analysis

Conduit Stock Analysis Notes

The company had not issued any dividends in recent years. For more info on Conduit Pharmaceuticals please contact the company at 646 491 9132 or go to https://www.conduitpharma.com.

Conduit Pharmaceuticals Investment Alerts

Conduit Profitablity

Management Efficiency

The company has return on total asset (ROA) of (2.0695) % which means that it has lost $2.0695 on every $100 spent on assets. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Conduit Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to climb to 2.23 in 2026, whereas Return On Assets are likely to drop (4.01) in 2026. At this time, Conduit Pharmaceuticals' Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 506 M in 2026, despite the fact that Non Currrent Assets Other are likely to grow to (1.2 B).

Technical Drivers

As of the 31st of January, Conduit Pharmaceuticals shows the Risk Adjusted Performance of 0.0257, downside deviation of 11.95, and Mean Deviation of 8.41. Conduit Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Conduit Pharmaceuticals coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Conduit Pharmaceuticals is priced correctly, providing market reflects its regular price of 0.0063 per share. As Conduit Pharmaceuticals appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Conduit Pharmaceuticals Price Movement Analysis

Conduit Pharmaceuticals Insider Trading Activities

Conduit Pharmaceuticals Outstanding Bonds

Conduit Pharmaceuticals Predictive Daily Indicators

Conduit Pharmaceuticals Forecast Models

Conduit Pharmaceuticals' time-series forecasting models are one of many Conduit Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Conduit Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Conduit Pharmaceuticals Bond Ratings

Conduit Pharmaceuticals financial ratings play a critical role in determining how much Conduit Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Conduit Pharmaceuticals' borrowing costs.

Conduit Pharmaceuticals Total Assets Over Time

Conduit Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Conduit Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Conduit Pharmaceuticals Debt Ratio

168.0

It appears most of the Conduit Pharmaceuticals' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Conduit Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Conduit Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Conduit Pharmaceuticals Corporate Bonds Issued

Conduit Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Conduit Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Conduit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Conduit Pharmaceuticals. By using and applying Conduit Stock analysis, traders can create a robust methodology for identifying Conduit entry and exit points for their positions.

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.